cozaar 50mg tablets - search results

merck sharp & dohme (new zealand) limited - losartan potassium 100mg; - film coated tablet - 100 mg - active: losartan potassium 100mg excipient: carnauba wax lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose powdered cellulose pregelatinised maize starch titanium dioxide - hypertension cozaar is indicated for the treatment of hypertension. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy cozaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy heart failure cozaar is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to cozaar is not recommended. renal protection in type 2 diabetic patients with proteinuria cozaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

cozaar

merck sharp & dohme (new zealand) limited - losartan potassium 12.5mg; - film coated tablet - 12.5 mg - active: losartan potassium 12.5mg excipient: carnauba wax hyprolose hypromellose indigo carmine lactose monohydrate magnesium stearate microcrystalline cellulose starch as pregelatinized corn starch 1500 titanium dioxide - hypertension cozaar is indicated for the treatment of hypertension. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy cozaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy heart failure cozaar is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to cozaar is not recommended. renal protection in type 2 diabetic patients with proteinuria cozaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

cozaar

merck sharp & dohme (new zealand) limited - losartan potassium 25mg; - film coated tablet - 25 mg - active: losartan potassium 25mg excipient: carnauba wax lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose powdered cellulose pregelatinised maize starch purified water titanium dioxide - hypertension cozaar is indicated for the treatment of hypertension. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy cozaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy heart failure cozaar is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to cozaar is not recommended. renal protection in type 2 diabetic patients with proteinuria cozaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.